MBXBF
Microbix Biosystems Inc.·Healthcare
0.17
0.000%(+0.00)
Market OpenLast Updated: — ET
52W L: $0.1552W H: $0.30
MBXBF NEWS
accessnewswire.com
Mar 26
Microbix Announces Annual Meeting Voting Results
MISSISSAUGA, ON / ACCESS Newswire / March 26, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQB:MBXBF) ("Microbix® " or the Company"), a life sciences innovator, manufacturer, and exporter, announces the voting results from the Annual Meeting of Shareholders of the Company (the "Meeting") which was held on March 25, 2026. At the Meeting, 27.44% of the issued and outstanding shares were represented.
seekingalpha.com
Mar 25
Microbix Biosystems Inc. (MBX:CA) Shareholder/Analyst Call Transcript
Microbix Biosystems Inc. (MBX:CA) Shareholder/Analyst Call Transcript
accessnewswire.com
Mar 17
Microbix Presents Reference-Material Innovations at EUROGIN
QUANTDx Samples with "Normalized" Viral Loads for Validating HPV Assays MISSISSAUGA, ON / ACCESS Newswire / March 17, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of novel QUANTDx™ reference materials designed to emulate real-life human papillomavirus ("HPV") patient-samples and thereby better support the validation of molecular (e.g., "PCR") tests for infection.
accessnewswire.com
Mar 10
Microbix's Clot-Buster Drug Project Advances
Drug Substance Manufacturing Methods Modernized MISSISSAUGA, ON / ACCESS Newswire / March 10, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that the contract development and manufacturing organization ("CDMO") engaged by its funding and commercialization partner, Sequel Pharma, LLC ("Sequel"), has modernized production methods for the active ingredient (i.e., "Drug Substance") of Kinlytic® urokinase ("Kinlytic"), a biologic for dissolving blood clots.
accessnewswire.com
Feb 24
Microbix Announces Issuance of Stock Options
Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, ON / ACCESS Newswire / February 24, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, announces the issuance of stock options under its shareholder-approved stock option plan (the "Stock Option Plan"), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers. Details of the Option Issuance In consultation with management, Microbix's Board of Directors has approved the issuance of 2,600,000 options in accordance with the terms of the Stock Option Plan.
seekingalpha.com
Feb 12
Microbix Biosystems Inc. (MBX:CA) Q1 2026 Earnings Call Transcript
Microbix Biosystems Inc. (MBX:CA) Q1 2026 Earnings Call Transcript
